Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Revenue Per Share for the year ending December 31, 2023: USD 0.03

Oncopeptides AB (publ) Revenue Per Share is USD 0.03 for the year ending December 31, 2023, a 182.76% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Oncopeptides AB (publ) Revenue Per Share for the year ending December 31, 2022 was USD 0.01, a -94.40% change year over year.
Oncopeptides AB (publ) Revenue Per Share for the year ending December 31, 2021 was USD 0.17, a 0.00% change year over year.
Oncopeptides AB (publ) Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Oncopeptides AB (publ) Revenue Per Share for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years